Metronidazole leads to enhanced uptake of imatinib in brain, liver and kidney without affecting its plasma pharmacokinetics in mice

Journal of Pharmacy and Pharmacology

Volumn 63, Issue 7, 2011, Pages 918-925

  Tan, Shin Yee ^a   Kan, Elaine ^a   Lim, Wei Yin ^a   Chay, Grace ^a   Law, Jason H K ^a   Soo, Gian Wan ^a   Bukhari, Nadeem Irfan ^a   Segarra, Ignacio ^a,b  

^a INTERNATIONAL MEDICAL UNIVERSITY   (Malaysia)

^b UNIVERSIDAD SAN JORGE   (Spain)

Author keywords

brain drug delivery; drug drug interaction; imatinib; metronidazole; tissue distribution

Indexed keywords

IMATINIB; METRONIDAZOLE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG INHIBITION; DRUG LIVER LEVEL; DRUG PENETRATION; DRUG POTENTIATION; DRUG SCREENING; DRUG UPTAKE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; KIDNEY; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; ANTIPROTOZOAL AGENTS; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; ENZYME INHIBITORS; HALF-LIFE; MALE; METABOLIC CLEARANCE RATE; METRONIDAZOLE; MICE; MICE, INBRED ICR; P-GLYCOPROTEINS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RANDOM ALLOCATION; TISSUE DISTRIBUTION;

EID: 79958040084     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2011.01296.x     Document Type: Article

References (39)

1. Scripture CD, Figg WD,. Drug interactions in cancer therapy. Nat Rev Cancer 2006; 6: 546-558. (Pubitemid 43980543)
2. Buchdunger E, et al,. Pharmacology of imatinib (STI571). Eur J Cancer 2002; 38 (Suppl): S28-S36.
3. Castillo M, et al,. C-KIT expression in sarcomatoid renal cell carcinoma: potential therapy with imatinib. J Urol 2004; 171: 2176-2180. (Pubitemid 38625429)
4. Wen PY, et al,. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium study 99-08. Clin Cancer Res 2006; 12: 4899-4907. (Pubitemid 44338577)
5. Peng B, et al,. Clinical pharmacokinetics of imatinib. Clin Pharmacokin 2005; 44: 879-894. (Pubitemid 41252840)
6. Gschwind HP, et al,. Metabolism and disposition of imatinib in healthy volunteers. Drug Metab Dispos 2005; 33: 1503-1512.
7. Neville K, et al,. Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates. Clin Cancer Res 2004; 10: 2525-2529. (Pubitemid 38445714)
8. Teoh M, et al,. HPLC analysis of imatinib in plasma and tissues after multiple oral dose administration to mice. Pak J Pharm Sci 2010; 23: 35-41.
9. Teoh M, et al,. Pharmacokinetics, tissue distribution and bioavailability of imatinib in mice after administration of a single oral and an intravenous bolus dose. Lat Am J Pharm 2010; 29: 428-435.
10. Altintas A, et al,. Central nervous system blastic crisis in chronic myeloid leukemia on imatinib mesylate therapy: a case report. J Neurooncol 2007; 84: 103-105. (Pubitemid 47103451)
11. Bihorel S, et al,. Scherrmann. Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec) across the mouse blood-brain barrier. J Neurochem 2007; 102: 1749-1755.
12. Baruchel S, et al,. A Canadian paediatric brain tumor consortium (CPBTC) phase II molecularly targeted study of imatinib in recurrent and refractory paediatric central nervous system tumours. Eur J Cancer 2009; 45: 2236-2238.
13. Wen PY, et al,. Phase II study of imatinib mesylate for recurrent meningiomas. Neuro-oncology 2009; 11: 853-860.
14. Wolff NC, et al,. The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia. Blood 2003; 101: 5010-5013. (Pubitemid 36857766)
15. Soo GW, et al,. Differential effects of ketoconazole and primaquine on the pharmacokinetics and tissue distribution of imatinib in mice. Anti-Cancer Drugs 2010; 21: 695-703.
16. Schwartz DE, Jeunet F,. Comparative pharmacokinetic studies of ornidazole and metronidazole in man. Chemotherapy 1976; 22: 19-29.
17. Tsai TH, Chen YF,. Pharmacokinetics of metronidazole in rat blood, brain and bile studied by microdialysis coupled to microbore liquid chromatography. J Chromatogr A 2003; 987: 277-282.
18. Jensen JC, Gugler R,. Single- and multiple-dose metronidazole kinetics. Clin Pharmacol Ther 1983; 34: 481-487. (Pubitemid 13016978)
19. Bersani C, et al,. PEG-metronidazole conjugates: synthesis, in vitro and in vivo properties. Il Farmaco 2005; 60: 783-788. (Pubitemid 41317705)
20. Cooke CE, et al,. Possible pharmacokinetic interaction with quinidine: ciprofloxacin or metronidazole? Ann Pharmacother 1996; 30: 364-366. (Pubitemid 26107692)
21. Page RL, et al,. Potential elevation of tacrolimus trough concentrations with concomitant metronidazole therapy. Ann Pharmacother 2005; 39: 1109-1113.
22. Blyden GT, et al,. Metronidazole impairs clearance of phenytoin but not of alprazolam or lorazepam. J Clin Pharmacol 1988; 28: 240-245. (Pubitemid 19014772)
23. Roedler R, et al,. Does metronidazole interact with cyp3a substrates by inhibiting their metabolism through this metabolic pathway? Or should other mechanisms be considered? Ann Pharmacother 2007; 41: 653-658. (Pubitemid 46625489)
24. Nassar I, et al,. Reduced exposure of imatinib after coadministration with acetaminophen to mice. Indian J Pharmacol 2009; 41: 167-172.
25. Bailer AJ,. Testing for the equality of area under the curves when using destructive measurement techniques. J Pharmacokinet Biopharm 1988; 16: 303-309.
26. Yuan J,. Estimation of variance for AUC in animal studies. J Pharm Sci 1993; 82: 761-763. (Pubitemid 23315700)
27. Naderer OJ, et al,. The influence of norfloxacin and metronidazole on the disposition of mycophenolate mofetil. J Clin Pharmacol 2005; 45: 219-226. (Pubitemid 40490446)
28. Cho MJ, et al,. Metronidazole phosphate-a water-soluble prodrug for parenteral solutions of metronidazole. J Pharm Sci 1982; 71: 410-414. (Pubitemid 12123800)
29. Matheny CJ, et al,. Pharmacokinetic and pharmacodynamic implications of p-glycoprotein modulation. Pharmacotherapy 2001; 21: 778-796. (Pubitemid 32606791)
30. Nielsen ML, Justesen T,. Excretion of metronidazole in human bile. Investigations of hepatic bile, common duct bile, and gallbladder bile. Scand J Gastroenterol 1977; 12: 1003-1008. (Pubitemid 8257830)
31. Chourasia MK, Jain SK,. Pharmaceutical approaches to colon targeted drug delivery systems. J Pharm Pharmaceut Sci 2003; 6: 33-66. (Pubitemid 37207241)
32. Cattelotte J, et al,. In situ mouse carotid perfusion model: glucose and cholesterol transport in the eye and brain. J Cereb Blood Flow Metab 2008; 28: 1449-1459.
33. Davies B, Morris T,. Physiological parameters in laboratory animals and humans. Pharm Res 1993; 10: 1093-1095. (Pubitemid 23211439)
34. Ren H, et al,. Differential effect of imatinib and synergism of combination treatment with chemotherapeutic agents in malignant glioma cells. Basic Clin Pharmacol Toxicol 2009; 104: 241-252.
35. Reardon DA, et al,. Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. Br J Cancer 2009; 101: 1995-2004.
36. Desjardins A, et al,. Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. J Neurooncol 2007; 83: 53-60. (Pubitemid 46647165)
37. Nassar I, et al,. Histopathological study of the hepatic and renal toxicity associated to the coadministration of imatinib and acetaminophen in a preclinical mouse model. Malays J Pathol 2010; 32: 1-11.
38. Lim AYL, et al,. Histopathology and biochemistry analysis of the interaction between sunitinib and paracetamol in mice. BMC Pharmacol 2010; 10: 14 (1-17).
39. Picard S, et al,. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007; 109: 3496-3499. (Pubitemid 46572540)